Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 16/20 | 0.72 |
| ▸ | TNF | P01375 | 4/20 | 0.51 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200967 | 0.93 | ADAM17 (0.71) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL7943649 | 0.90 | ADAM17 (0.74) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL10200976 | 0.89 | ADAM17 (0.76) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL10200961 | 0.89 | ADAM17 (0.72) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL7940662 | 0.87 | ADAM17 (0.68) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL10199384 | 0.85 | ADAM17 (0.79) | ADAM17TNF | |
| SCHEMBL7943251 | 0.85 | ADAM17 (0.83) | ADAM17TNF | |
| SCHEMBL7941661 | 0.85 | ADAM17 (0.72) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL7941555 | 0.85 | ADAM17 (0.60) | ADAM17TNFADAM10MMP1MMP2 | |
| SCHEMBL10200905 | 0.85 | ADAM17 (0.78) | ADAM17TNFADAM10MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | ADAM17 8/4885TNF 1/4885ADAM10 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.